- Home
- KYMR vs ARQT Comparison
KYMR vs ARQT Comparison
Compare KYMR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- ARQT
- Stock Information
- Founded
- KYMR 2015
- ARQT 2016
- Country
- KYMR United States
- ARQT United States
- Employees
- KYMR N/A
- ARQT 342
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- ARQT Health Care
- Exchange
- KYMR Nasdaq
- ARQT Nasdaq
- Market Cap
- KYMR 1.8B
- ARQT 1.7B
- IPO Year
- KYMR 2020
- ARQT 2020
- Fundamental
- Price
- KYMR $30.53
- ARQT $13.17
- Analyst Decision
- KYMR Buy
- ARQT Strong Buy
- Analyst Count
- KYMR 13
- ARQT 6
- Target Price
- KYMR $56.69
- ARQT $18.80
- AVG Volume (30 Days)
- KYMR 762.3K
- ARQT 2.1M
- Earning Date
- KYMR 05-09-2025
- ARQT 05-06-2025
- Dividend Yield
- KYMR N/A
- ARQT N/A
- EPS Growth
- KYMR N/A
- ARQT N/A
- EPS
- KYMR N/A
- ARQT N/A
- Revenue
- KYMR $47,072,000.00
- ARQT $212,819,000.00
- Revenue This Year
- KYMR $16.24
- ARQT $57.99
- Revenue Next Year
- KYMR $22.41
- ARQT $41.24
- P/E Ratio
- KYMR N/A
- ARQT N/A
- Revenue Growth
- KYMR N/A
- ARQT 100.03
- 52 Week Low
- KYMR $19.45
- ARQT $6.99
- 52 Week High
- KYMR $53.27
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- KYMR 53.88
- ARQT 45.54
- Support Level
- KYMR $28.28
- ARQT $12.42
- Resistance Level
- KYMR $35.98
- ARQT $15.67
- Average True Range (ATR)
- KYMR 2.14
- ARQT 0.82
- MACD
- KYMR 0.01
- ARQT -0.05
- Stochastic Oscillator
- KYMR 50.71
- ARQT 43.69
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.